カテゴリ： GlobalData, 企業調査, 日本

Chugai Pharmaceutical Co Ltd (4519)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Chugai Pharmaceutical Co Ltd (4519) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9881
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：98
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：日本
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Chugai Pharmaceutical Co Ltd (Chugai) is a subsidiary of Hoffmann-La Roche Ltd, which focuses on the research, development, manufacture, commercialization, import and export of the biopharmaceuticals and therapeutic antibodies. The company offers products for the treatment of cancer; bone and joint diseases; renal diseases; immunology and infectious diseases and others. It also offers drugs to aid kidney, liver and other organ transplantations. It also has a range of product candidates in its pipeline. Operating through its network of subsidiaries, the company offers its pharmaceutical products in overseas markets including North America, Europe and Asia. Chugai is headquartered in Tokyo, Japan.

Chugai Pharmaceutical Co Ltd (4519) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 6
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deal Details 15
Partnerships 15
Helsinn Enters into Licensing Agreement with Chugai Pharma for Netupitant-Palonosetron Fixed-Dose Combination 15
Anaeropharma Science Enters into Research Agreement with Chugai Pharma 16
Chugai Pharma Enters into Research Agreement with National Cancer Center Japan 17
Astellas Pharm, Kyowa Hakko Kirin, Daiichi Sankyo, Eisai, Ono Pharma and Chugai Pharma to Enter into Agreemet with Four Research Institutions 18
Chugai Pharmaceutical Enters into Agreement with Osaka University 20
Chugai Pharma Enters Into Co-Development Agreement With Nippon Shinyaku For GA101 21
Licensing Agreements 22
Eli Lilly to Enter into Licensing Agreement with Chugai Pharma 22
Chugai Pharma Enters into Licensing Agreement with Roche 23
JW Pharma Enters into Licensing Agreement with Chugai Pharma 24
Chugai Pharma Enters into Licensing Agreement with SBI Pharma 25
Berlin-Chemie Enters into Licensing Agreement with Chugai Pharma 26
Galderma Pharma Enters into Licensing Agreement with Chugai Pharma 27
Roche Enters into Licensing Agreement with Chugai Pharma for Recycling Antibody SA237 28
Chugai Pharma Enters into Licensing Agreement with Two Cells 29
BioMarin Pharma Enters into Sub-license Agreement with Chugai Pharma 30
Kowa Company Enters into Licensing Agreement with Chugai Pharmaceutical 31
Roche Amends Licensing Agreement with Chugai Pharma 32
PharmaMar Enters into Licensing Agreement with Chugai Pharma for Aplidin 33
Chugai Pharma Enters into Licensing Agreement with Roche 34
Chugai Pharma Enters Into Licensing Agreement With Debiopharm Group For FF284 35
Chugai Pharma Expands Licensing Agreement with Kowa for DEBERZA 36
Maruho Enters into Licensing Agreement with Chugai Pharma 37
EpiVax Enters into Licensing Agreement with Chugai Pharma 38
Helsinn Enters Into Licensing Agreement With Chugai Pharma Marketing For Anamorelin 39
Chugai Pharma Extends Licensing Agreement With Genedata For Genedata Expressionist Software 40
Asset Transactions 41
Taiyo Pharma to Acquire Product Rights from Chugai Pharma and Roche 41
Eisai Acquires Rights to Manufacture Active Pharmaceutical Ingredients in Japan from Chugai Pharma and F. Hoffman-La Roche 42
Acquisition 43
Roche May Acquire 40% Stake in Chugai Pharma 43
Chugai Pharmaceutical Co Ltd – Key Competitors 44
Chugai Pharmaceutical Co Ltd – Key Employees 45
Chugai Pharmaceutical Co Ltd – Locations And Subsidiaries 47
Head Office 47
Other Locations & Subsidiaries 47
Joint Venture 49
Recent Developments 50
Strategy And Business Planning 50
Jul 27, 2018: Chugai Pharmaceutical to expand Singaporean research subsidiary 50
Jul 26, 2018: Chugai Pharmaceutical announce construction of a new synthetic research building to enhance process development for small and middle molecule APls 51
Jan 27, 2017: Aiming to Provide Solutions that Meet Changes of Regional Healthcare Services 52
Financial Announcements 53
Oct 24, 2018: Chugai Pharmaceutical: FY2018 3Q financial results 53
Corporate Communications 54
Oct 12, 2018: Chugai releases disease awareness anime about Rheumatoid Arthritis in multiple languages emphasizing importance of early detection/treatment and care by specialists 54
Jul 26, 2018: Chugai Pharmaceutical announces organizational and personnel changes 55
Dec 12, 2017: Notice on Change of Chief Executive Officer 56
Legal and Regulatory 57
Aug 29, 2018: Chugai obtains “Platinum Kurumin” certification from the minister of health, labour and welfare as a company supporting childrearing 57
Government and Public Interest 58
Mar 30, 2017: Chugai – ASTAR Joint Development Project for Anti-Dengue Virus Antibody Selected as Grant Recipient by the GHIT Fund 58
Product News 59
11/02/2017: Health Canada Approves ACTEMRA (tocilizumab) for Canadians Living with Giant Cell Arteritis 59
10/13/2017: CHMP recommends EU approval of Roche’s Alecensa (alectinib) as a first-line treatment for people with ALK-positive NSCLC 60
09/22/2017: Roche Receives European Approval for Actemra /RoActemra in Giant Cell Arteritis 61
08/30/2017: FDA approves Roche’s Actemra/RoActemra (tocilizumab) for the treatment of CAR T cell-induced cytokine release syndrome 62
08/25/2017: Approval of Actemra for Additional Indications of Takayasu Arteritis and Giant Cell Arteritis, Both are Designated Intractable Diseases 63
08/10/2017: Announcement of Commencement of Arbitration against Chugai 64
06/26/2017: Approval of Additional Dosage for “Actemra Subcutaneous Injection” Reducing Dose Interval to One Week in Patients with Rheumatoid Arthritis Who Inadequately Respond to Bi-weekly Dose 65
05/22/2017: FDA approves first drug to specifically treat giant cell arteritis 66
04/04/2017: NICE Terminates Appraisal for Alectinib in Previously Treated ALK-positive Advanced NSCLC 67
02/27/2017: Chugai’s ALK Inhibitor “Alecensa” Approved in Taiwan 68
02/21/2017: Roche receives EU approval of Alecensa (alectinib) for people with previously treated ALK-positive non-small cell lung cancer 69
Product Approvals 71
Mar 22, 2018: New Drug Application of Eldecalcitol, an Active Vitamin D3 Derivative, for the Treatment of Osteoporosis Accepted in China 71
Sep 01, 2017: Roche and MHRA to make treatment available for those newly diagnosed with a rare type of lung cancer in the UK before anywhere else in Europe 72
May 08, 2017: Roche’s Alecensa Rejects For Use Within NHS Scotland 73
Jan 23, 2017: FDA Grants Priority Review For Genentech’s Actemra (Tocilizumab) Supplemental Biologics License Application For Giant Cell Arteritis, a Form of Vasculitis 74
Clinical Trials 75
Nov 06, 2017: Eldecalcitol, an Active Vitamin D3 Derivative, Increases Bone Mineral Density of Osteoporosis Patients in Chinese Phase III Study 75
Oct 05, 2017: Chugais Bispecific Antibody ERY974 Results of Preclinical Study Published in Science Translational Medicine 76
Sep 06, 2017: Roche presents data from global phase III study showing significant clinical benefit of Alecensa (alectinib) in later-line advanced ALK-positive lung cancer 77
Aug 09, 2017: Genentech Completes Phase III Enrollment for Study of Actemra in Systemic Sclerosis 78
Aug 02, 2017: FDA Grants Genentech’s Alecensa Priority Review for Initial Treatment of People with ALK-Positive Lung Cancer 79
Jul 26, 2017: Positive Phase III Results of Genentech’s Actemra (Tocilizumab) for the Treatment of Giant Cell Arteritis Published in New England Journal of Medicine 81
Jul 25, 2017: Galderma Announces Enrollment of First Patient in Phase IIb Nemolizumab Trial in Atopic Dermatitis 83
Jul 21, 2017: Roche Gains Positive CHMP Opinion for Actemra / Roactemra in Giant Cell Arteritis 84
Jun 06, 2017: Alectinib potential new standard of care for ALK-positive non-small lung cancer 85
Jun 05, 2017: Phase III study showed Roche’s Alecensa (alectinib) reduced the risk of disease progression or death by more than half versus crizotinib as first-line treatment in a specific type of lung cancer 86
May 11, 2017: Results of the J-ALEX Study for Chugais Alecensa are Published in The Lancet Online 88
Apr 10, 2017: Phase III study shows Roche’s Alecensa was superior to crizotinib in a specific type of lung cancer 89
Apr 03, 2017: Phase III ALUR study supports the use of Roche’s Alecensa for people with advanced ALK-positive lung cancer 90
Mar 02, 2017: Chugai’s Anti-IL-31 Receptor A Humanized Monoclonal Antibody “nemolizumab (CIM331)” Global Phase II Study Data Published in The New England Journal of Medicine Online 92
Feb 08, 2017: Roche’s Alecensa (alectinib) approved in Switzerland for people with a specific type of lung cancer 93
Other Significant Developments 95
Oct 17, 2018: F. Hoffmann-La Roche announces third quarter sales 2018 95
Oct 01, 2018: Chugai Redesigns Corporate Website 96
Apr 04, 2017: A First Approach in the Japanese Pharmaceutical Industry Starting a Trial of a Drug Adherence Support App Using Multidisciplinary SNS for Outpatient Cancer Treatment 97
Appendix 98
Methodology 98
About GlobalData 98
Contact Us 98
Disclaimer 98

List of Tables
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Chugai Pharmaceutical Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 10
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Helsinn Enters into Licensing Agreement with Chugai Pharma for Netupitant-Palonosetron Fixed-Dose Combination 15
Anaeropharma Science Enters into Research Agreement with Chugai Pharma 16
Chugai Pharma Enters into Research Agreement with National Cancer Center Japan 17
Astellas Pharm, Kyowa Hakko Kirin, Daiichi Sankyo, Eisai, Ono Pharma and Chugai Pharma to Enter into Agreemet with Four Research Institutions 18
Chugai Pharmaceutical Enters into Agreement with Osaka University 20
Chugai Pharma Enters Into Co-Development Agreement With Nippon Shinyaku For GA101 21
Eli Lilly to Enter into Licensing Agreement with Chugai Pharma 22
Chugai Pharma Enters into Licensing Agreement with Roche 23
JW Pharma Enters into Licensing Agreement with Chugai Pharma 24
Chugai Pharma Enters into Licensing Agreement with SBI Pharma 25
Berlin-Chemie Enters into Licensing Agreement with Chugai Pharma 26
Galderma Pharma Enters into Licensing Agreement with Chugai Pharma 27
Roche Enters into Licensing Agreement with Chugai Pharma for Recycling Antibody SA237 28
Chugai Pharma Enters into Licensing Agreement with Two Cells 29
BioMarin Pharma Enters into Sub-license Agreement with Chugai Pharma 30
Kowa Company Enters into Licensing Agreement with Chugai Pharmaceutical 31
Roche Amends Licensing Agreement with Chugai Pharma 32
PharmaMar Enters into Licensing Agreement with Chugai Pharma for Aplidin 33
Chugai Pharma Enters into Licensing Agreement with Roche 34
Chugai Pharma Enters Into Licensing Agreement With Debiopharm Group For FF284 35
Chugai Pharma Expands Licensing Agreement with Kowa for DEBERZA 36
Maruho Enters into Licensing Agreement with Chugai Pharma 37
EpiVax Enters into Licensing Agreement with Chugai Pharma 38
Helsinn Enters Into Licensing Agreement With Chugai Pharma Marketing For Anamorelin 39
Chugai Pharma Extends Licensing Agreement With Genedata For Genedata Expressionist Software 40
Taiyo Pharma to Acquire Product Rights from Chugai Pharma and Roche 41
Eisai Acquires Rights to Manufacture Active Pharmaceutical Ingredients in Japan from Chugai Pharma and F. Hoffman-La Roche 42
Roche May Acquire 40% Stake in Chugai Pharma 43
Chugai Pharmaceutical Co Ltd, Key Competitors 44
Chugai Pharmaceutical Co Ltd, Key Employees 45
Chugai Pharmaceutical Co Ltd, Other Locations 47
Chugai Pharmaceutical Co Ltd, Subsidiaries 48
Chugai Pharmaceutical Co Ltd, Joint Venture 49

List of Figures
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

★海外企業調査レポート[Chugai Pharmaceutical Co Ltd (4519)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Navidea Biopharmaceuticals Inc (NAVB)：医療機器：M&Aディール及び事業提携情報
    Summary Navidea Biopharmaceuticals Inc (Navidea) is a biopharmaceutical company that develops precision immunodiagnostic agents and immunotherapeutics.. The company is focused on developing multiple precision-targeted products based on its Manocept platform to improve patient care. Its pipeline prod …
  • Lotte Holdings Co. Ltd.：企業の戦略・SWOT・財務情報
    Lotte Holdings Co. Ltd. - Strategy, SWOT and Corporate Finance Report Summary Lotte Holdings Co. Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • EPAM Systems Inc (EPAM)：企業の財務・戦略的SWOT分析
    EPAM Systems Inc (EPAM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Scholastic Corp (SCHL)：企業の財務・戦略的SWOT分析
    Scholastic Corp (SCHL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Botswana Power Corporation-エネルギー分野：企業M&A・提携分析
    Summary Botswana Power Corporation (BPC) is a parastatal utility that generates, transmits and distributes electricity. Its transmission network connects various towns in Botswana such as Maun, Shakawe, Gumare, Ghanzi, Pandamatenga and Kasane. BPC distributes electricity to areas approved by the Min …
  • Chevron Corp (CVX)：企業の財務・戦略的SWOT分析
    Chevron Corp (CVX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Diversicare Healthcare Services Inc (DVCR)：企業の財務・戦略的SWOT分析
    Summary Diversicare Healthcare Services Inc (Diversicare), formerly Advocat Inc is a healthcare service provider that offers post acute care services and short term rehabilitation and long-term care services to nursing home patients. The company offers services such as life steps rehabilitation prog …
  • Flexion Therapeutics Inc (FLXN)：企業の財務・戦略的SWOT分析
    Flexion Therapeutics Inc (FLXN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Alabama Municipal Electric Authority：電力：M&Aディール及び事業提携情報
    Summary Alabama Municipal Electric Authority (AMEA) is a not-for-profit publicly-owned electric utility that generates, procures, and supplies power. The authority generates electricity from sources such as gas and solar. AMEA procures electricity from open market and South Carolina Public Service A …
  • BNP Paribas SA：企業のM&A・事業提携・投資動向
    BNP Paribas SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's BNP Paribas SA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • Manz AG (M5Z)：電力：M&Aディール及び事業提携情報
    Summary Manz AG (Manz) is a manufacturer of high-technology equipment. It produces displays, printed circuit boards and other components for electronic devices. The company provides production equipment for lithium-ion battery cells, super capacitors, battery systems, and capacitors. Manz offers ind …
  • Beijing Enterprises Holdings Ltd：企業の戦略・SWOT・財務情報
    Beijing Enterprises Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Beijing Enterprises Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Color Genomics Inc：医療機器：M&Aディール及び事業提携情報
    Summary Color Genomics, Inc. (Color) provides physician ordered genetic testing service that helps to identify hereditary cancer risk. The company’s clinical grade test provides actionable results that enable consumers and their doctors to create personalized screening and healthcare plan. Color ana …
  • Navitas Limited (NVT)：企業の財務・戦略的SWOT分析
    Navitas Limited (NVT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Software AG：企業の戦略・SWOT・財務情報
    Software AG - Strategy, SWOT and Corporate Finance Report Summary Software AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • HealthEquity Inc (HQY)：企業の財務・戦略的SWOT分析
    Summary HealthEquity Inc (HealthEquity) is a healthcare service provider that offers health savings management services. The company provides integrated health accounts such as health savings account, health reimbursement arrangements, flexible spending accounts for health plans, and health incentiv …
  • UTStarcom Holdings Corp. (UTSI)：企業の財務・戦略的SWOT分析
    UTStarcom Holdings Corp. (UTSI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Al Waha Capital P.J.S.C.：企業の戦略・SWOT・財務情報
    Al Waha Capital P.J.S.C. - Strategy, SWOT and Corporate Finance Report Summary Al Waha Capital P.J.S.C. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Sumi-Eagle Corp：企業の戦略的SWOT分析
    Sumi-Eagle Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • SIGA Technologies Inc (SIGA)：企業の財務・戦略的SWOT分析
    Summary Siga Technologies Inc (Siga) a subsidiary of MacAndrews and Forbes Holdings Inc, is a health security service provider. The company develops and commercialise solutions for serious unmet medical needs and bio threats. It offers antiviral drug to treat smallpox disease. Siga offers product su …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆